All In Biotech

Drug Trial Radar · NCT05453903

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

196

Actual

Start

Oct 4, 2022

Primary completion

Oct 30, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • BleximenibDrug

    Participants will receive bleximenib.

  • Venetoclax (VEN)Drug

    Participants will receive VEN.

  • Azacitidine (AZA)Drug

    Participants will receive AZA.

  • CytarabineDrug

    Participants will receive cytarabine.

  • Daunorubicin or IdarubicinDrug

    Participants will receive daunorubicin or idarubicin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to 3 Years 3 months
  2. Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 3 Years 3 months
  3. Number of Participants with Dose-limiting Toxicity (DLT)Time frame: End of Cycle 1 (28 days)

Locations

32 sites in 8 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • City of Hope

    Duarte, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Albert Einstein College Of Medicine

    New York, New York

  • Novant Health

    Charlotte, North Carolina

  • Novant Health Forsyth Medical Center

    Winston-Salem, North Carolina

  • MD Anderson

    Houston, Texas

  • Monash Medical Centre

    Clayton, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Westmead Hospital

    Westmead, Australia

  • Princess Margaret Cancer Centre University Health Network

    Toronto, Ontario, Canada

  • Institut Paoli Calmettes

    Marseille, France

  • Chu Rennes Hopital Pontchaillou

    Rennes, France

  • Institut Universitaire du Cancer Toulouse Oncopole

    Toulouse, France

  • CHU de Tours - Hôpital de Bretonneau

    Tours, France

  • Charite Universitaetsmedizin Berlin

    Berlin, Germany

  • Universitatsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany

  • Universitaetsklinikum Leipzig

    Leipzig, Germany

  • Universitatsklinikum Ulm

    Ulm, Germany

  • Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna

    Bologna, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • IRCCS Istituto Clinico Humanitas

    Rozzano, Italy

  • Hosp Clinic de Barcelona

    Barcelona, Spain

  • Hosp. de La Santa Creu I Sant Pau

    Barcelona, Spain

  • Hosp Univ Vall D Hebron

    Barcelona, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain

  • Clinica Univ. de Navarra

    Pamplona, Spain

  • University College London Hospitals NHSFT

    London, United Kingdom

  • Christie Hospital NHS Trust

    Manchester, United Kingdom

  • Oxford University Hospitals NHS Trust

    Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.